Go to content Go to the menu Go to the search

Home - Federative Research Institute
Immunity - Cancer - Infection



 faculte de medecine UPMC




The IFR 113 Immunity-Cancer-Infection comprises 15 research teams working on the topics of the institute. Beyond the individual projects of each partner - including studies of the immune system under normal and pathological conditions, of infectious agents and cancer - strong interactions are generated linking immunity and infection, immunity and cancer as well as cancer and infection. These very strong links and the close cooperation between laboratories involved in basic research with clinical departments of the Pitié-Salpêtrière hospital are characteristic for the activities of IFR 113 and provide for quality, originality and innovation. Ultimately, these interactions underlie the international reputation of the institute.
The IFR is headed by Prof. Brigitte Autran and Prof. David Klatzmann and aims to coordinate the following research programs:

  • studies of host-pathogen interactions for 3 important infectious diseases - HIV, mycobateria and plasmodium - focussing on physiological and pathophysiological mechanisms of innate and adaptive immunity,
  • epidemiological, clinical and microbiological investigations of infectious agents - HIV, HCV/HBV, Herpesvirus, mycobacteria, plasmodium - addressing propagation, anti-infectious therapies and microbial multiresistance appearing after these treatments,
  • studies of the immune-modulatory effects mediated by regulatory T cells in close relation with systemic inflammatory pathologies and auto-immune diseases,
  • investigations on biodiversity including (i) the spontaneous and treatment induced genetic diversity of pathogens, (ii) human genetics relevant to infectious diseases, (iii) post-genomic transcriptional and proteomic analyses and (iv) the system biology of pathogens and hosts,
  • studies of cancer addressing control by the immune system and relation with infectious pathogens.

Ultimately, innovative vaccines and biotherapies are developed. The activities range from pre-clinical experimental studies to the set-up of phase I / II clinical trials. The approaches take advantage of state of the art cell transplantation and gene transfer technology.